Tag: pharmacologic ascorbate

Anti-cancer effect of pharmacologic ascorbate and its interaction with supplementary parenteral glutathione in preclinical cancer models

This 2011 study by Chen et al. investigates the anti-cancer effects of high-dose intravenous ascorbic acid (AA) and its interaction with intravenous glutathione (GSH) in preclinical cancer models. The research demonstrates that pharmacologic concentrations of AA induce cytotoxicity in various cancer cell lines through the generation of hydrogen peroxide (H₂O₂),

Read More »

Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice

This 2008 preclinical study revealed that pharmacologic doses of ascorbate (vitamin C), administered intravenously or intraperitoneally, act as a prooxidant by generating hydrogen peroxide (H₂O₂) selectively within the tumor microenvironment. In vitro, this resulted in H₂O₂-dependent cytotoxicity in a range of cancer cell lines while sparing normal cells. In vivo,

Read More »

Cytotoxic effects of high concentrations of sodium ascorbate on human myeloid cell lines

This 2015 study investigates the cytotoxic potential of pharmacologic doses of sodium ascorbate (vitamin C) on several human myeloid leukemia cell lines, including HL60, U937, NB4, NB4-R4 (retinoic acid-resistant), NB4/AsR (arsenic trioxide-resistant), and K562. Results showed that sodium ascorbate induced dose-dependent apoptosis with an LC50 around 3 mM, primarily through

Read More »

High-Dose Intravenous Vitamin C, a Promising Multi-Targeting Agent in the Treatment of Cancer

This 2021 review explores the therapeutic potential of high-dose intravenous vitamin C (IVC) in oncology, emphasizing its role as a multi-targeting agent. Pharmacologic doses of IVC exert pro-oxidative effects that selectively induce cancer cell apoptosis by generating hydrogen peroxide in the tumor microenvironment. The review outlines additional mechanisms, including modulation

Read More »